Search PubMedSearch

Biomedical subjects

J Guédon

Publications and source records attributed to J Guédon.

At least 19 recordsLinked to original sources

[Renovascular hypertension and beta blockers. Theoretical and practical implications].

Beta blockade was instituted in 10 patients with renovascular hypertension due to renal artery stenosis or thrombosis. The treatment was very effective in unilateral stenosis with a normal contralateral kidney (2 kidney Goldblatt) and in fibromuscular dystrophy of the renal artery. On the other hand many failures were observed in hypertension with a single kidney (1 kidney Goldblatt) and in renovascular hypertension with complex lesions or associated renal failure. Although a clear relationship was often observed between the increased plasma renin activity and the antihypertensive effect of beta blockade, this association was sometimes completely erroneous. Beta blockade, which is easy to perform, should be tried out systematically in renovascular hypertension, but, when no result is observed, this therapeutic test should not exclude surgical management thereafter.

Adrenergic beta-Antagonists

[Study of acebutolol dialysis and pharmacokinetic data in patients with renal insufficiency undergoing hemodialysis].

The dialysance of acebutolol, in vitro, has been found to be equal to 87 ml/mn for a blood flow of 200 ml/mn through an artificial kidney; at the same flow rate, that of urea is 136 ml/mn. In subjects with normal renal function, half-life of acebutolol in plasma, after oral administration, is 4.4 +/- 0.6 h; in haemodialysed patients with renal failure, it is very increased; during haemodialysis, it is near normal (mean: 5.9 h in 4 subjects). Authors discuss the meaning of acebutolol dialysance, in vivo, considering a possible protein binding of this drug.

Acebutolol

[Acebutolol in the treatment of arterial hypertension. Clinical study].

Fifty hypertensive patients were given a beta-blocker, acebutolol, alone or in association with other hypotensive drugs, in an open therapeutic trial lasting for a year. The results of treatment were considered to be good or moderate in 74 p.cent of the patients. Treatment failures were recorded in 26 p.cent. The mean dosage of acebutolol was 10 mg/kg (maximum 22 mg/kg) and the drug was very well tolerated. Hypertension with an increased cardiac index and reno-vascular hypertension with increased plasma renin activity are good indications for acebutolol.

Acebutolol

[Test with trinitrine. Clinical evaluation of the beta anti-adrenergic effect of acebutolol in arterial hypertension].

The beta-adrenergic stimulation test with nitroglycerin, described by Fitzgerald, was used to monitor antihypertensive treatment with the beta-blocker acebutolol in 30 hypertensive patients. The nitroglycerin-induced tachycardia was reduced by acebutolol and this allowed the degree of beta-blockage to be estimated. It would also be possible, by tests performed before treatment, to select hypotensive patients who could be highly responsive to beta-adrenergic blockers, for whom there are the best prospects of success.

Acebutolol

Late streptokinase therapy in thrombotic microangiopathy: a case study.

A 42 year woman presented with malignant hypertension, anuria and hemolytic anemia with schistocytosis. The diagnosis of thrombotic microangiopathy was confirmed by early renal biopsy. Purely symptomatic treatment (peritoneal dialysis and hypotensive drugs) was supplemented by administration of heparin and Dipyridamole. Gastro-intestinal bleeding prevented early thrombolytic therapy. Microangiopathic anemia rapidly disappeared but anuria persisted. Three months later a second renal biopsy showed persistence of active lesions and absence of irreversible parenchymal damage. Streptokinase treatment was then instituted and followed by a rapid return of urinary output. Hemodialysis was stopped and renal function continued to improve over the following months. Two years later the patient remains well despite persistence of hypertension difficult to control. Creatinine clearance is stable at 20 ml/min. This observation suggests that late thrombolytic therapy may be effective in patients with thrombotic microangiopathy when histological findings do not indicate extensive irreversible lesions.

Adult